The real cost of RSV, a common but often fatal disease
RESCEU have put together the most comprehensive cache of evidence to date on the true burden of a disease that still claims millions of mostly infant victims every year
Image by Blanscape via Shutterstock
Anyone can catch respiratory syncytial virus, and most people are infected before their fifth birthday. Symptoms can vary from mild to deadly. Young children are at greatest risk, though it can also be serious for older people and those with other health problems. To try to get the full picture of how much of an impact the disease has on populations and public health systems, a team of researchers, policy makers, pharma sector representatives and patient advocates came together under the RESCEU project to produce an evidence-based tally of the costs of the disease, with the ultimate aim of using the data to feed public health strategies.